Literature DB >> 27635069

Outcomes of Transvenous Lead Extraction for Cardiovascular Implantable Electronic Device Infections in Patients With Prosthetic Heart Valves.

Xin-Miao Huang1, Hai-Xia Fu1, Li Zhong1, Jiang Cao2, Samuel J Asirvatham1, Larry M Baddour1, M Rizwan Sohail1, Vuyisile T Nkomo1, Rick A Nishimura1, Kevin L Greason1, Rakesh M Suri1, Paul A Friedman1, Yong-Mei Cha2.   

Abstract

BACKGROUND: Lead-related or valve-related endocarditis can complicate cardiovascular implantable electronic device (CIED) infection in patients with both CIED and prosthetic valves. The objective of this study was to determine the outcomes of transvenous lead extraction for CIED infection in patients with prosthetic valves. METHODS AND
RESULTS: We retrospectively screened 794 transvenous lead extraction procedures, between September 1, 2001 and August 31, 2012, at Mayo Clinic to identify patients with prosthetic valves who underwent lead extraction for infection. Demographic, clinical, and follow-up characteristics were analyzed. In total, 51 patients (6%) met the study inclusion criteria, of whom 20 had pocket infection and 31 had lead-related or valve-related, or both, endocarditis or bloodstream infection (mean age, 67 [18] years). Staphylococcal species were the most common pathogens, including Staphylococcus aureus in 20 cases (39%) and coagulase-negative staphylococci in 19 cases (37%). Overall, 127 transvenous leads (median lead age, 52 months) were extracted. Of these leads, 123 (97%) were removed completely. The in-hospital mortality rate was 9.8%; no deaths were attributable to the extraction procedure. Ninety-five percent of patients who survived had no evidence of recurrent device-related or valve-related infection.
CONCLUSIONS: Transvenous lead extraction seems safe and curative in patients with CIED infection and prosthetic valves. Cure of infection can be achieved in the majority of patients with complete CIED removal and antimicrobial therapy and without valve surgery.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  Staphylococcal infections; anti-infective agents; cardiovascular infections; endocarditis; retrospective studies

Mesh:

Substances:

Year:  2016        PMID: 27635069     DOI: 10.1161/CIRCEP.116.004188

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  3 in total

1.  Risk Factors for Mortality in Cardiac Implantable Electronic Device (CIED) Infections: A Systematic Review and Meta-Analysis.

Authors:  Jinghao Nicholas Ngiam; Tze Sian Liong; Meng Ying Sim; Nicholas W S Chew; Ching-Hui Sia; Siew Pang Chan; Toon Wei Lim; Tiong-Cheng Yeo; Paul Anantharajah Tambyah; Poay Huan Loh; Kian Keong Poh; William K F Kong
Journal:  J Clin Med       Date:  2022-05-29       Impact factor: 4.964

2.  European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).

Authors:  Carina Blomström-Lundqvist; Vassil Traykov; Paola Anna Erba; Haran Burri; Jens Cosedis Nielsen; Maria Grazia Bongiorni; Jeanne Poole; Giuseppe Boriani; Roberto Costa; Jean-Claude Deharo; Laurence M Epstein; Laszlo Saghy; Ulrika Snygg-Martin; Christoph Starck; Carlo Tascini; Neil Strathmore
Journal:  Europace       Date:  2020-04-01       Impact factor: 5.214

Review 3.  Cardiac Implantable Electronic Devices Infection Assessment, Diagnosis and Management: A Review of the Literature.

Authors:  Filippo Toriello; Massimo Saviano; Andrea Faggiano; Domitilla Gentile; Giovanni Provenzale; Alberto Vincenzo Pollina; Elisa Gherbesi; Lucia Barbieri; Stefano Carugo
Journal:  J Clin Med       Date:  2022-10-06       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.